Positive Initial Topline Data from Ongoing Phase 1 Clinical Trial could make This Today’s Trade
DENVER, Colo., Dec 13, 2023 (247marketnews.com)- Shattuck Labs, Inc. (NASDAQ:STTK) reported, this morning, initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. Initial data from the dose-expansion cohorts build on the complete dose-escalation data featured in a poster presentation on December 11, 2023 at the 65th ASH Annual Meeting.
Observations include a 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64%; 27% initial CR/complete response with incomplete hematologic recovery (CRi) in frontline TP53m AML patients, and 5/11 evaluable patients achieved stable disease with decreasing blast counts and peripheral blood count improvement, these patients continue on treatment; and SL-172154 demonstrated an acceptable safety and tolerability profile as a monotherapy and in combination with azacitidine (AZA) –
Shattuck Labs is trading at $2.88, up $0.77 (+36.49%), on 1.8M shares traded.
Its 52-week range is $1.3301 to $4.765. This is trading at multi-month highs and it’s already set a new 52-week trading volume high. It doesn’t have much resistance after $3 and, as long as the volume remains strong, this could set a new 52-week high price.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.
Few succeed in the stock market. Don’t trade if you’re not able to devote the necessary time. Earmark your surplus funds that you’re prepared to lose. Assess your risk appetite and set your stops accordingly, and honor your stop losses. Always employ loss limiting strategies. Be prepared to be blindsided by hidden risks, a bad company financing or other move can turn gains into losses.
Learn technical analysis, charting, patterns, and setups. Buying at the bottom and selling at the top is a myth. The middle half of a move is the sweet spot and learn how to exit a winning position, because trying to time the exact top can turn into big losses. Trade small and take advantage of small price move strategies, like scalping.
Remove emotional and psychological biases, and consider that you’re competing against professionals who’re deploying a number of powerful stock market tools. Successful traders make more on their winners than they lose on their losers. Learn how to interpret the ECN/Level 2 data.
Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.